Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06588322

Detection of Homologous Recombination Pathway Gene Mutations in Circulating Tumour DNA From BRCA-mutated Ovarian Cancer Patients Receiving First-line PARP Inhibitor Maintenance Therapy

This is an interventional (category 2), prospective, multicentric cohort study designed to demonstrate that the search, based on Circulating tumour DNA analysis, for a BRCA1/2 reversion mutation leading to restoration of its protein function enables early identification of disease progression in BRCA1/2 mutant patients treated as first-line maintenance with a PARP inhibitor (Olaparib alone or in combination with bevacizumab) for ovarian cancer.

For this study, a total of 9 blood samples will be taken from patients who will undergo a full 24-month treatment regimen.

Apart from the study procedure (blood sampling), all examinations carried out in this study, treatment with Olaparib (alone or combined with bevacizumab) and patient follow-up procedures will be carried out as part of routine care in accordance with the standard practices of each investigating site.

130 patients will take part in the study, and each patient will be followed for 24 months.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Ovarian Cancer Adnexal Diseases Endocrine Gland Neoplasms Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Genital Neoplasms, Female Gonadal Disorders Neoplasms Neoplasms by Site Ovarian Diseases Ovarian Neoplasms Urogenital Diseases Urogenital Neoplasms

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

INSTITUT DE CANCEROLOGIE DE L'OUEST - Site Angers, Angers, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient with an epithelial ovarian cancer, fallopian tube cancer or primitive of the peritoneum.
  • Patient with a BRCA 1 or 2 somatic and/or constitutional mutation previously confirmed and validated by an approved laboratory.
  • Patient due to start first-line maintenance treatment with Olaparib alone (PARP inhibitor) or in combination with bevacizumab.
  • Age ≥ 18 years at the time of signing the consent.
  • WHO ≤ 1.
  • Patient affiliated to a Social Security scheme in France.
  • Patient having signed informed consent prior to inclusion in the study and prior to any specific procedure for the study.

Exclusion criteria

  • Other cancer under treatment.
  • Olaparib treatment already initiated.
  • Indication for treatment with a PARP inhibitor other than Olaparib.
  • Any pathology contraindicating the sample collection procedures required by the study.
  • Any psychological, family, geographical or sociological condition that makes it impossible to comply with medical monitoring and/or the procedures laid down in the study protocol.
  • Subjects deprived of their liberty or under legal protection.

Treatment and study plan

Blood samples will be taken on several times (36 mL of blood taken at each time):

Other
  • Inclusion visit (T0): prior to initiation of Olaparib treatment
  • Follow-up period (T1 to T8): every 3 months for a maximum of 24 months
  • End of study (Tx): on definitive cessation of Olaparib treatment for any reason (progression, toxicity or definitive cessation of treatment after 2 years).

Primary outcomes

  1. The rate of patients (in the population of patients with disease progression) with disease progression that was preceded by the detection of BRCA1/2 reversion mutation in circulating tumour DNA (i.e. Sensitivity).

    Time frame: 24 months for each patient

    Sensitivity is defined as the ratio of the number of disease progression events in which a reversion mutation was detected early to the number of disease progression events.

Secondary outcomes

  1. The rate of patients with BRCA 1/2 reversion mutations at inclusion.

    Time frame: 24 months for each patient

    It is defined as the ratio of the number of patients with BRCA 1 / 2 reversion mutations at inclusion to the total number of patients.

  2. Progression-free survival.

    Time frame: 24 months for each patient

    It is defined as the time between the date of inclusion and the date of progression or death from any cause. Patients alive without progression at the date of last news are censored.

  3. The concordance between the type/location of the germline or somatic BRCA1/2 mutation and the BRCA1/2 reversion mutation will be presented in the form of a contingency table.

    Time frame: 24 months for each patient

  4. The rates of patients with mutations in the other genes of the HR pathway at inclusion and at relapse.

    Time frame: 24 months for each patient

    It will be defined respectively by the ratio of the number of patients with reversion mutations at inclusion to the total number of patients and by the ratio of the number of patients with reversion mutations at relapse to the total number of patients with relapse.

Study contacts

Contact information is provided by the study sponsor or research team.

Laurence GLADIEFF

CONTACT

[email protected]

05 31 15 51 01

Sponsors and collaborators

Lead sponsor

Institut Claudius Regaud

Other

Registry information

Acronym: ATROVA

Important dates

Study start
2025
Primary completion
2029
Study completion
2029
First posted
Sep 19, 2024
Registry last updated
Nov 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.